早期采用和处方模式的resmetirom:一个多机构的国家分析
Kate Solpari1, Zane Gouda1, Allysa Saggese1
1Division of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, New York, USA.
概括
作为FDA批准的第一种治疗先进纤维化非循环性MASH的疗法,Resmetirom显示早期处方模式有利于代谢负担较高的患者. 然而,在符合条件的人群中观察到显著的不足利用和潜在的非标签使用.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- Resmetirom是FDA批准的第一种治疗中度至晚期纤维化非循环性MASH的疗法,于2024年3月获得批准.
- 具有肝纤维化的非循环性MASH (NASH) 代表着日益增长的未满足的医疗需求.
- 了解早期处方模式对于评估现实世界治疗吸收至关重要.
研究的目的:
- 评估在非循环性MASH和中度至高级纤维化患者中早期处方resmetirom的模式.
- 为了确定与resmetirom启动相关的患者特征.
- 评估在适宜接受治疗的人群中使用resmetirom的情况.
主要方法:
- 使用TriNetX研究网络进行的回顾性队列研究.
- 包括44个医疗保健组织的3712名患者.
- 对resmetirom和其他常见药物的处方数据的分析,包括GLP-1受体激活剂.
主要成果:
- 在19643名符合条件的患者中,resmetirom被处方给了1057名治疗患者中的5.4%.
- 接受治疗的患者更有可能是亚裔或西班牙裔,并被处方GLP-1受体激动剂,他类药物,甲型胺或ARBs.
- 常见的并发症包括脂质不良,高血压和2型糖尿病; 72%的人患有MASLD,56%的人患有MASH诊断.
结论:
- 早期的resmetirom处方有利于具有较高代谢负担的患者.
- 潜在的错误编码,非标签的使用,以及符合条件的人群中显著的不足利用需要进一步调查.
- 关于resmetirom使用的现实数据将为临床实践和患者获取信息提供信息.
相关概念视频
01:26Oral Drug Delivery Systems: Continuous-Release Systems
135
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
135
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
309
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
309
01:21Factors Affecting Drug Response: Overview
3.2K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.2K
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
626
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
626
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
349
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
349
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
1.2K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.2K